Trial Profile
Single-arm phase II study of panitumumab rechallenge in combination with oxaliplatin or irinotecan-based chemotherapy in patients with RAS wild type advanced colorectal cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms A-REPEAT
- 04 Dec 2021 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 04 Jun 2021 This trial has been Discontinued in Cyprus, according to European Clinical Trials Database record.
- 02 Jun 2021 Status changed from active, no longer recruiting to discontinued.